NCT02499848View on ClinicalTrials.gov

Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Prostate Cancer
Interventions
DRUG

PRX302

Single prostate cancer lesion injected with PRX302.

Trial Locations (1)

Unknown

UCLH, London

All Listed Sponsors
lead

Sophiris Bio Corp

INDUSTRY

NCT02499848 - Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer | Biotech Hunter | Biotech Hunter